Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533602 | 0.79 | MEN1 (0.39) | MEN1KMT2ACSNK2A2RAB9ACSNK2B | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.79 | GDA (0.48) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | PDPK1GDACDK2DPP4ALDH1A1 | |
| 6-Chloroguanine SCHEMBL6711 | 0.76 | DPP4 (0.52) | PDPK1GDAPRKACACSNK2A1DYRK1A | |
| SCHEMBL1336872 | 0.76 | PDPK1 (0.37) | PDPK1GDAMEN1KMT2ACDK2 | |
| SCHEMBL2938699 | 0.76 | PDPK1 (0.37) | PDPK1GDACDK2DPP4ALDH1A1 | |
| Guanine SCHEMBL31714144 | 0.76 | BRAF (0.38) | PDPK1GDAPRKACAMEN1KMT2A | |
| Thioguanine SCHEMBL218891 | 0.76 | PDPK1 (0.37) | PDPK1GDACDK2DPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2711009-A1 | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711008-A1 | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711007-A1 | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021029334-A1 | RNA INTERFERENCE AGENT, MULTIPLE CHEMICALLY MODIFIED OLIGONUCLEOTIDE, AND USE THEREOF | 国立大学法人東海国立大学機構 | 2021-02-18 | — | — | WO | disclosed |
| EP-0174272-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | disclosed |
| EP-0175641-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-02-24 | — | — | EP | disclosed |
| US-4644069-A | HEATING MALEIC ACID OR ANHYDRIDE WITH AN AMIDINE OR ITS SALT | CIBA-GEIGY CORPORATION (US) | 1987-02-17 | — | — | US | disclosed |
| US-4639531-A | HETEROCYCLIC AMIDINE CATALYST | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0175641-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-26 | — | — | EP | disclosed |
| EP-0174272-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PDPK1 18/4885GDA 273/4885PRKACA 279/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PDPK1 18/4885GDA 273/4885PRKACA 279/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PDPK1 19/4885GDA 1662/4885PRKACA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.